Synapse - Howard Scher

Search Within

Howard Scher

Results (159)

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Research Letter

Samstein, R. M.; Lee, C. H.; Shoushtari, A. N.; Hellmann, M. D.; Shen, R.; Janjigian, Y. Y.; Barron, D. A.; Zehir, A.; Jordan, E. J.; Omuro, A.; more...
Nature Genetics (2019)

Fulltext@MSK | Save

Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP plus D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP)

Meeting Abstract

Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Vaishampayan, U. N.; Shevrin, D. H.; Harrison, M. R.; Tagawa, S. T.; Milowsky, M. I.; Graff, J. N.; Beer, T. M.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Estimation of tumor-derived mutant allele fractions in cfDNA by shallow whole genome sequencing and fragment size analysis

Meeting Abstract

Yang, J.; Marass, F.; Ulz, P.; Shady, M.; Cheng, M. L.; Kothari, P.; Gedvilaite, E.; Somnay, S.; Shukla, N.; Modak, S.; more...
Cancer Research (2018)

Fulltext@MSK | Save

Oncologic therapy for solid tumors alters the risk of clonal hematopoiesis

Meeting Abstract

Bolton, K.; Ptashkin, R.; Braunstein, L.; Kelly, D.; Devlin, S. M.; Coombs, C. C.; Moarii, M.; Patel, M.; Bernard, E.; Berthon, A.; more...
Blood (2018)

Fulltext@MSK | Save

Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Winquist, E.; McLaughlin, B.; Lu, D.; Orr, S.; Fleisher, M.; Lowes, L.; Anderson, A. K. L.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer

Journal Article

Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Jayaram, A.; Winquist, E.; McLaughlin, B.; Lu, D.; Fleisher, M.; Orr, S.; Lowes, L.; more...
JAMA Oncology (2018)

Fulltext@MSK | Save

Reply to C. Ren et al

Journal Article

Heller, G.; McCormack, R.; Kheoh, T.; Molina, A.; Smith, M. R.; Dreicer, R.; Saad, F.; de Wit, R.; Aftab, D. T.; Hirmand, M.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Positron emission tomography/computed tomography-based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer

Journal Article

Fox, J. J.; Gavane, S. C.; Blanc-Autran, E.; Nehmeh, S.; Gonen, M.; Beattie, B.; Vargas, H. A.; Schoder, H.; Humm, J. L.; Fine, S. W.; more...
JAMA Oncology (2018)

Fulltext@MSK | Save

Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: A comparison with prostate-specific antigen across five randomized phase III clinical trials

Journal Article

Heller, G.; McCormack, R.; Kheoh, T.; Molina, A.; Smith, M. R.; Dreicer, R.; Saad, F.; de Wit, R.; Aftab, D. T.; Hirmand, M.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer

Meeting Abstract

Razavi, P.; Li, B.; Abida, W.; Aravanis, A.; Jung, B.; Shen, R.; Hou, C.; De Bruijn, I.; Gnerre, S.; Lim, R. S.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save